Your session is about to expire
← Back to Search
Ibrutinib + Brentuximab Vedotin for Hodgkin's Lymphoma
Study Summary
This trial is testing ibrutinib and brentuximab vedotin to see if they are effective in treating patients with Hodgkin lymphoma that has returned or does not respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the FDA sanctioned Ibrutinib as a viable medical remedy?
"Due to a lack of efficacy data, our team has placed Ibrutinib on the conservative side with a safety rating of 2."
For what ailment is Ibrutinib typically prescribed?
"To treat cell transplants, chronic lymphocytic leukemia (CLL), and Hodgkin Disease, ibrutinib offers a viable solution."
How many participants have been enrolled in this experiment?
"Unfortunately, recruitment for this medical study has ceased. The trial was initially posted on June 20th 2016 and its most recent update occurred on September 1st 2022. For those seeking alternative studies, there are presently 1724 clinical trials in search of patients with hodgkin disease as well as 213 separate trails searching for participants to take Ibrutinib."
Are there any additional investigations involving Ibrutinib?
"Currently, 213 studies are ongoing that focus on ibrutinib. Out of those trials 29 have progressed to Phase 3 status. The majority of these investigations for this medication are based in Montvale, NJ however there is a global presence with 9051 sites running clinical studies into the benefits of iburtinib."
How revolutionary is this medical research in comparison to prior studies?
"Ibrutinib research began in 2011, when Seagen Inc. conducted its initial trial involving 79 patients - thus granting the drug a Phase 2 approval. Nowadays, this medication is being studied across 47 countries and 1405 cities with 213 active studies taking place."
Is the trial currently open to enrollees?
"According to clinicaltrials.gov, this trial is not presently enrolling patients - the first post was on June 20th 2016 and it underwent a revision in September 1st 2022. Despite that, 1937 other studies are accessible for potential participants at present."
Share this study with friends
Copy Link
Messenger